Zepto Life Technology

Executive Summary

Zepto Life Technology Inc. is a U.S.-based diagnostics company specializing in a highly-sensitive, multiplexed molecular diagnostics platform. Founded in 2015 and headquartered in St. Paul, Minnesota, the company operates a CLIA-certified reference laboratory and offers contract research organization (CRO) services. Zepto aims to improve diagnostic standards and patient outcomes by commercializing its proprietary platform for infectious disease, oncology, and genetic testing. As a private company with a focus on clinical development and lab services, Zepto is positioned to address unmet needs in rapid, accurate, and multi-analyte testing. The company has not disclosed funding or valuation details, but its lab operations and platform suggest potential for near-term revenue generation and partnerships. However, as a smaller player in the competitive diagnostics space, its success hinges on regulatory approvals, adoption by healthcare providers, and securing capital for expansion. Zepto's integrated model of providing both testing services and a commercial platform offers diversified revenue streams, but scalability and market penetration remain key risks.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or CLIA waiver for a lead diagnostic test35% success
• Q3 2026Strategic partnership or licensing deal with a larger diagnostics or pharmaceutical company40% success
• Q2 2026Series B or significant funding round to scale operations and commercialization50% success